Identification by virtual screening and in vitro testing of human DOPA decarboxylase inhibitors
about
Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening MethodologiesCrystal structure of the S187F variant of human liver alanine: Aminotransferase associated with primary hyperoxaluria type I and its functional implicationsLigand pose and orientational sampling in molecular dockingParkinson's disease-associated melanin stealEffects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathyThe Parkinson's disease death rate: carbidopa and vitamin B6.Targeting cystalysin, a virulence factor of treponema denticola-supported periodontitis.Exploration of natural product ingredients as inhibitors of human HMG-CoA reductase through structure-based virtual screening.Biochemical and computational approaches to improve the clinical treatment of dopa decarboxylase-related diseases: an overviewIn silico studies in drug research against neurodegenerative diseases.Riboflavin Has Neuroprotective Potential: Focus on Parkinson's Disease and Migraine.Parkinson's disease managing reversible neurodegeneration.Structural mimicry between SLA/LP and Rickettsia surface antigens as a driver of autoimmune hepatitis: insights from an in silico study.Parkinson's disease: carbidopa, nausea, and dyskinesia.PLP-dependent enzymes.Interaction of human Dopa decarboxylase with L-Dopa: spectroscopic and kinetic studies as a function of pH.Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.S250F variant associated with aromatic amino acid decarboxylase deficiency: molecular defects and intracellular rescue by pyridoxine.Aminooxy analog of histamine is an efficient inhibitor of mammalian L-histidine decarboxylase: combined in silico and experimental evidence.
P2860
Q26745421-2159A845-795A-4F63-BC2C-34ADDB356788Q27677394-10B772AE-7E6F-4DE9-8737-B2F5C4CEF838Q28533958-706C7018-6B13-48DD-9C35-DAE0261A1386Q30422756-9174B4ED-A744-4D08-89B8-285C5A087A10Q33695388-0AE3F384-0CE8-4057-B31F-A03A540C686CQ34415308-87AF734B-C4EC-4EAC-B24C-F3A04777CDC2Q35116929-D68CAB55-479E-4E3F-821F-D8A23F5EE75EQ35821951-DF14D51A-A654-4F09-8354-1F8BF4269137Q38069579-1663F132-FE3F-44B2-855C-9579326119AEQ38638421-E024206C-6ED2-4768-815B-E45E30F7510CQ38647109-9BDD4C26-0856-4DD0-9806-CAA46B02A2D5Q40030359-5B3C3442-8D9A-4572-A48A-F0CE20FE32A3Q40101922-7190A09E-C10B-4043-8CF2-96BC76AEC9F8Q41780193-361A4A53-2E90-4E11-94CE-B56E6B2CB4CFQ41820414-9AE1084A-2C60-4267-8845-698A7B17FF64Q42147273-F8E3AB25-1ACF-414E-A582-825FDBA99194Q47962428-15E5E64E-7D50-49F5-AF49-79E33668B8D7Q51755232-20684F43-6DCD-4498-AFC9-70F762AF548FQ54751860-8DBF8368-0309-4E40-B995-DB6B3300DBDB
P2860
Identification by virtual screening and in vitro testing of human DOPA decarboxylase inhibitors
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Identification by virtual scre ...... DOPA decarboxylase inhibitors
@ast
Identification by virtual scre ...... DOPA decarboxylase inhibitors
@en
Identification by virtual scre ...... DOPA decarboxylase inhibitors
@nl
type
label
Identification by virtual scre ...... DOPA decarboxylase inhibitors
@ast
Identification by virtual scre ...... DOPA decarboxylase inhibitors
@en
Identification by virtual scre ...... DOPA decarboxylase inhibitors
@nl
prefLabel
Identification by virtual scre ...... DOPA decarboxylase inhibitors
@ast
Identification by virtual scre ...... DOPA decarboxylase inhibitors
@en
Identification by virtual scre ...... DOPA decarboxylase inhibitors
@nl
P2093
P2860
P3181
P1433
P1476
Identification by virtual scre ...... DOPA decarboxylase inhibitors
@en
P2093
Alessandro Paiardini
Barbara Cellini
Carla Borri Voltattorni
Francesco Bossa
Frederick Daidone
Riccardo Montioli
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0031610
P407
P577
2012-01-01T00:00:00Z